FDA approves 1st pediatric treatment for rare heart condition

The FDA has approved Camzyos (mavacamten) capsules as the first treatment for children with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. Camzyos is now approved for adults and pediatric patients weighing at least 30 kilograms (approximately 66 pounds) with symptomatic oHCM, according to a Sept. 30 FDA news release. The drug was […] The post FDA approves 1st pediatric treatment for rare heart condition appeared first on Becker's Hospi...